Search Results

Filterlex’s Captis Embolic Protection Device Evaluated With TAVR in FIH Study

May 31, 2022—Filterlex Medical Ltd., an Israel-based cardiovascular medical device startup, announced results from a first-in-human (FIH) study demonstrating the safety, feasibility, and performance of the Captis embolic protection device.

Filterlex Medical Completes Funding Round for Its Captis Clinical Program

November 18, 2021—Filterlex Medical Ltd., a cardiovascular medical device startup company based in Israel, announced that it has recently completed a $6 million Series A1 investment round from leading private health care investors.

Medtronic’s Evolut Pro+ TAVR System Approved in Europe

May 3, 2021—Medtronic announced CE Mark approval of the Evolut Pro+ transcatheter aortic valve replacement (TAVR) system.

Filterlex Medical’s Captis Embolic Protection Device for TAVR Evaluated in First-in-Human Study

November 15, 2023—Filterlex Medical Ltd., a cardiovascular medical device startup based in Israel, announced the publication of a first-in-human (FIH) study of the safety and feasibility of the company’s next-generation Captis full-body embolic protection device during transcatheter aortic valve replacement (TAVR) procedures.